Document is current
Any future updates will be listed below
-
Authors
Jones, J R
Cairns, D A
Gregory, W M
Collett, C
Pawlyn, C https://orcid.org/0000-0002-7190-0028
Sigsworth, R
Striha, A https://orcid.org/0000-0003-3363-8417
Henderson, R
Kaiser, M F
Jenner, M
Cook, G
Russell, N H
Williams, C
Pratt, G
Kishore, B
Lindsay, J
Drayson, M T
Davies, F E
Boyd, K D
Owen, R G
Jackson, G H
Morgan, G J
,
- License Information
-
More Information
Article History
Received: 2 September 2016
Accepted: 24 October 2016
First Online: 9 December 2016
Competing interests
: JRJ has received research and travel support from Celgene; WG: honoraria from Janssen and Celgene; CP: advisory board, honoraria and travel support from Celgene, Novartis and Takeda; MK: honoraria, consultancy, research funding and travel support from Celgene, BristolMyerSquibb (BMS), Chugia, Janssen and Takeda; MJ: honoraria from Takeda and Janssen; GC: consultancy and research funding from Janssen, Celgene, Takeda Oncology, Sanofi, Amgen and BMS; GP: Celgene Honoraria; BK: Celgene and Jazz Pharmaceuticals; FD: honoraria and travel support from Takeda-Milenium, Onyx-Amgen, Celgene and Janssen; KB: honoraria and travel support from Celgene and Janssen; RGO: honoraria and research funding from Celgene and Janssen; GHJ: honoraria from Celgene, Takeda and Amgen; GJM: honoraria, advisory committee, research funding; CancerNet, Multiple Myeloma Research Foundation, Celgene, Takeda-Millennium, BMS and Weisman Institute. The remaining authors declare no conflict of interest.
